Grail, Inc. (NASDAQ:GRAL – Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 5,300,000 shares, a decrease of 14.5% from the January 15th total of 6,200,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 5.2 days. Approximately 18.9% of the shares of the stock are short sold.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on GRAL. Wolfe Research started coverage on shares of Grail in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Morgan Stanley initiated coverage on shares of Grail in a research report on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 price target on the stock.
Check Out Our Latest Stock Report on Grail
Grail Trading Up 4.6 %
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in GRAL. Douglas Lane & Associates LLC acquired a new position in Grail during the 4th quarter worth $3,034,000. A. D. Beadell Investment Counsel Inc. acquired a new stake in Grail in the fourth quarter worth about $430,000. FNY Investment Advisers LLC bought a new stake in Grail during the 4th quarter worth about $26,000. 180 Wealth Advisors LLC acquired a new position in Grail during the 4th quarter valued at about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management bought a new position in shares of Grail in the 4th quarter valued at about $387,000.
About Grail
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
- Five stocks we like better than Grail
- CD Calculator: Certificate of Deposit Calculator
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Buy P&G Now, Before It Sets A New All-Time High
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Why Are These Companies Considered Blue Chips?
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.